Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BerGenBio ASA ( (BRRGF) ) has provided an update.
BerGenBio ASA announced the approval of its 2024 Annual Financial Statements by the Board of Directors, prepared according to International Financial Reporting Standards. The company will only publish half-yearly financial reports due to an ongoing strategic review and cost-saving initiatives, and the Annual General Meeting has been postponed to June 26, 2025. This decision reflects BerGenBio’s efforts to streamline operations and manage resources effectively, potentially impacting its financial transparency and stakeholder engagement.
More about BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company based in Bergen, Norway, with a subsidiary in Oxford, UK. The company is focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer. BerGenBio is listed on the Oslo Stock Exchange under the ticker BGBIO.
YTD Price Performance: 25.00%
Technical Sentiment Signal: Buy
Current Market Cap: $6.84M
For detailed information about BRRGF stock, go to TipRanks’ Stock Analysis page.